International Life Sciences Awards 2019

GHP / International Life Sciences Awards 2019 13 , Epione Biopharmaceuticals Epione Biopharmaceuticals: Best for Non-Addictive Injectable Pain Management Solutions - USA A pioneer in the painmanagement market, Epione Biopharmaceuticals is striving towards creating non-additive, injectable painmanagement products that will revolutionise the global healthcare space. In celebration of the firm’s win in our 2019 International Life Sciences Awards we profile it and share an insight into how far the company has come over the past four years. In the healthcare market currently, the growing worldwide incidence of acute and chronic pain, and the increasing occurrences of migraines have led to widespread consequences for both the global healthcare system and the economy. First-line pain treatments are typically opiate- based medications; however, concerns regarding side effects, prescription drug abuse, risk of overdose, patient non-adherence to treatment regimens (accelerated dosing), and lack of efficacy in certain conditions provide challenges to providers, patients, regulators, and increasingly, law enforcement. Legislators, policy makers, public health officials, law enforcement, physicians, pharmacists, and patients are all grappling with the consequences of the prevalence and abuse of opiates in our society. The crisis presents an enormous opportunity for a company to bring a non-addictive, non-opioid, and highly effective pain medication to this market. Working to overcome these issues and provide a revolution in the market, Epione was formed in 2015 to provide the benefits of highly efficacious, injectable medications for the treatment of pain in multiple markets without the burden and risks that opiate- based therapies offer. Since its inception Epione has focused on developing drug- device combinations that are safe and non-addictive, non-opioid, and putting control back in the patient’s hands. The formulation of the firm’s solutions is safe and non-addictive, but also highly efficacious. The formulation is not an opioid, but studies on the formulation and its constituent compounds demonstrate that it can provide opiate-level pain relief in multiple etiologies of pain. It has also been demonstrated to be opiate-sparing, allowing patients to reduce or eliminate their use of opiates. Overall, having won this prestigious accolade, the future looks bright for Epione. This award serves as international validation of our concept and is well timed for the firm’s upcoming plans. The team are pressing forward with human factor trials for the pen-injector product delivery system, and have received a funding commitment from a development partner and will seek additional funding in the coming months to complete this and future phases of Epione’s development, leading to a targeted submission in late 2020. Contact Details: Epione Biopharmaceuticals Name: Milton Kleinpeter Address: Epione Biopharmaceuti- cals, 8414 Bluebonnet Blvd. Suite 110, Baton Rouge, LA, 70810 Telephone Number: 225-363-8977 Web Address: epionebio.com “Working to overcome these issues and provide a revolution in the market, Epione was formed in 2015 to provide the benefits of highly efficacious, injectable medications for the treatment of pain in multiple markets without the burden and risks that opiate-based therapies offer.”